In 8 patients requiring acute neuroendovascular stenting, cangrelor plus aspirin achieved adequate platelet inhibition in 100% of cases with no intraprocedural or hemorrhagic complications.
Is cangrelor plus aspirin safe and effective for platelet inhibition in patients requiring acute stenting during neuroendovascular treatment?
Cangrelor plus aspirin appears to be a safe and effective strategy for achieving immediate platelet inhibition in patients requiring acute stenting during neuroendovascular procedures.
BACKGROUND: Treatment of acute cerebrovascular pathology, such as acute ischemic stroke or intracranial aneurysms, presents a challenge if an extracranial or intracranial stent is required; immediate platelet inhibition is vital. To date, there is no standardized approach for antiplatelet inhibition in an acute setting. OBJECTIVE: To report our preliminary experience and lessons learnt using cangrelor in acute neurointervention. METHODS: A single-arm pilot study was performed to assess the safety and efficacy of cangrelor plus aspirin for platelet inhibition in patients who require acute stenting in the setting of neuroendovascular treatment. RESULTS: Eight patients were enrolled between October 2017 and August 2018. Median age was 71 years (53-86). Seven patients were treated in an acute setting according to the stroke protocol at our institution, while one patient was treated for a symptomatic, unruptured aneurysm with flow diversion and coiling. At admission, the median National Institutes of Health Stroke Scale score for the patients with stroke was 12.5 (range 2-22.3). Cangrelor was infused and all patients achieved adequate platelet inhibition (<200 PRU (P2Y12 reaction units)). Six of seven patients with ischemic stroke had a carotid stent placed and one had an intracranial stent deployed in the middle cerebral artery. None of the patients experienced intraprocedural thromboembolic complications, intraprocedural in-stent thrombosis, hemorrhagic complications, or stroke within 24 hours after the intervention. The majority of patients (6/8) had a good clinical outcome at discharge (modified Rankin Scale score 0-2). CONCLUSIONS: Our findings suggest that cangrelor is a promising alternative in acute stenting for the treatment of cerebrovascular pathology. However, further studies with larger samples are required to accurately elucidate its safety and effectiveness in neuroendovascular procedures.
Aguilar‐Salinas et al. (Fri,) conducted a other in Acute cerebrovascular pathology requiring acute stenting (n=8). Cangrelor plus aspirin was evaluated on Adequate platelet inhibition (<200 PRU). In 8 patients requiring acute neuroendovascular stenting, cangrelor plus aspirin achieved adequate platelet inhibition in 100% of cases with no intraprocedural or hemorrhagic complications.